Advertisement
U.S. markets open in 5 hours 12 minutes
  • S&P Futures

    5,205.50
    -9.25 (-0.18%)
     
  • Dow Futures

    39,207.00
    -16.00 (-0.04%)
     
  • Nasdaq Futures

    18,168.25
    -63.25 (-0.35%)
     
  • Russell 2000 Futures

    2,046.40
    -3.40 (-0.17%)
     
  • Crude Oil

    82.50
    -0.22 (-0.27%)
     
  • Gold

    2,156.00
    -8.30 (-0.38%)
     
  • Silver

    25.11
    -0.15 (-0.59%)
     
  • EUR/USD

    1.0850
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.47
    +0.14 (+0.98%)
     
  • GBP/USD

    1.2689
    -0.0040 (-0.31%)
     
  • USD/JPY

    150.4190
    +1.3210 (+0.89%)
     
  • Bitcoin USD

    64,240.49
    -3,691.85 (-5.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,728.44
    +5.89 (+0.08%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Gilead Sciences Beats Street and Doubles Sales with Q2 Sovaldi Update

Gilead Sciences shares rose sharply in after-hours trading on Wednesday after the company reported second quarter results which surpassed analyst forecasts. The biotech company posted profits of $2.23 a share, far higher than the $1.79 analysts had been expecting. Revenue came in at $6.53 billion, that was also better than estimates. Gilead reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago because of its Sovaldi sales. Sovaldi helps cure Hepatitis C in people with HIV. It was prescribed to over 800,000 patients since its launch in December, generating almost half of the company’s sales. The Street's Kathryn Mykleseth reports from New York.

Advertisement